LSD1/ER-IN-1 

LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC₅₀ of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC₅₀ of 8.79 μM^[1].

LSD1/ER-IN-1 (compound 11g) (0-30 μM, 24 h) induces apoptosis in MCF-7 cells in a dose-dependent manner^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

455.46

C₂₃H₁₈FNO₆S

O=S(C1[C@H]2C(C3=CC=C(O)C=C3)=C(C4=CC=C(O)C=C4)[C@@H](C1)O2)(OC5=NC(F)=CC=C5)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. He M, et al. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer. Eur J Med Chem. 2020 Jun 1;195:112281.  [Content Brief]